Cohort 1 Pregnant women will be excluded from both Cohort 1 if the drug is IVM and . Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs Cohort 2 If the drug is Aspirin. Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs Some clinical characteristics will exclude participants from some of the severe pneumonia arms: PaTS-COVID Trial: Protocol Version 1.3_17 August 2020 o Patients already on steroids will be excluded from the dexamethasone arm if applicable o Active untreated or inactive tuberculosis for the deaxamethasone arm if applicable o Known bleeding disorder for aspirin if applicable o Prolonged QTc – excluded from azithromycin if applicable

Cohort 1 Pregnant women will be excluded from both Cohort 1 if the drug is IVM and . Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs Cohort 2 If the drug is Aspirin. Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs Some clinical characteristics will exclude participants from some of the severe pneumonia arms: PaTS-COVID Trial: Protocol Version 1.3_17 August 2020 o Patients already on steroids will be excluded from the dexamethasone arm if applicable o Active untreated or inactive tuberculosis for the deaxamethasone arm if applicable o Known bleeding disorder for aspirin if applicable o Prolonged QTc – excluded from azithromycin if applicable